Patents by Inventor Tohru Tanaka
Tohru Tanaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970662Abstract: An electrochromic element including: a first electrode; a second electrode disposed to face the first electrode with a gap between the first electrode and the second electrode; a first electrochromic layer disposed on or above the first electrode, including conductor or semiconductor nano-structures and an electrochromic compound; and an electrolyte layer including an electrolyte, disposed between the first electrochromic layer and the second electrode, wherein the electrochromic compound is a compound represented by General Formula 1, and an anion of the electrolyte is a monovalent anion having oxidation potential higher than reduction potential of a dication of General Formula 1 by 3.1 V or greater, where X? is a monovalent anion having oxidation potential higher than reduction potential of the dication of General Formula 1 by 3.Type: GrantFiled: July 29, 2020Date of Patent: April 30, 2024Assignee: RICOH COMPANY, LTD.Inventors: Fuminari Kaneko, Daisuke Goto, Masato Shinoda, Ryo Kawamura, Naru Tanaka, Tohru Yashiro, Mamiko Inoue, Naoki Ura
-
Publication number: 20240118170Abstract: A vibration monitoring device includes: a rotation sensor for outputting a rotation signal synchronized with rotation of a rotational shaft; an output device for outputting a filter command value corresponding to a rotation speed of the rotational shaft calculated from the rotation signal; and at least one filter for extracting, in response to input of the rotation signal and the filter command value, a signal in a passband set according to the filter command value from the rotation signal as a vibration signal from which vibration information of the rotational shaft can be obtained.Type: ApplicationFiled: February 15, 2022Publication date: April 11, 2024Applicant: Mitsubishi Heavy Industries Marine Machinery & Equipment Co., Ltd.Inventors: Tadashi Yoshida, Hidetaka Nishimura, Akifumi Tanaka, Shinji Ogawa, Isao Tomita, Tohru Suita, Ryoji Sasaki
-
Publication number: 20240097441Abstract: A management system includes a plurality of resources configured to be electrically connected to an external power supply, and a management device configured to manage the resources. The management device includes a planning unit and a management unit. The planning unit is configured to determine a power balancing plan of each of the resources by using first information on a use schedule of each of the resources and second information indicating a magnitude of an environmental load in a process of generating electric power to be supplied by the external power supply. The management unit is configured to manage the resources to cause each of the resources to operate according to the power balancing plan or a modified power balancing plan in power balancing of the external power supply.Type: ApplicationFiled: August 3, 2023Publication date: March 21, 2024Applicants: TOYOTA JIDOSHA KABUSHIKI KAISHA, CHUBU ELECTRIC POWER MIRAIZ CO., INC., CHUBU ELECTRIC POWER CO., INC.Inventors: Yusuke HORII, Eiko Megan UCHIDA, Masashi TANAKA, Masato EHARA, Sachio TOYORA, Tomoya TAKAHASHI, Akinori MORISHIMA, Takuji MATSUBARA, Tohru NAKAMURA, Ryou TAKAHASHI, Kenta ITO, Toshiki SUZUKI, Atsushi MIYASHITA, Takashi OCHIAI
-
Publication number: 20230313806Abstract: An electric compressor includes: a housing of an electric motor that is a power source of a compressor unit; a rotor that rotates inside the housing of the electric motor; a coil spring biasing the rotor in a rotation axis direction; a bearing interposed between the electric motor and the housing of the electric motor, and including an inner ring held by the rotor, and an outer ring biased by the coil spring to abut against an abutting portion of the housing of the electric motor; and a stopper that prohibits the rotor from displacing beyond a predetermined limit displacement amount against the biasing of the coil spring, and that allows the rotor to displace within the limit displacement amount. When the rotor is displaced to the limit displacement amount, the coil spring after being deformed has a closed height or more.Type: ApplicationFiled: June 8, 2023Publication date: October 5, 2023Inventor: Tohru TANAKA
-
Publication number: 20230190690Abstract: The present invention provides a therapeutic and/or preventive agent for coronavirus disease 2019 (COVID-19) comprising 5-aminolevulinic acid (ALA) or its derivative or a salt thereof and provides a method for treating and/or preventing coronavirus disease 2019 (COVID-19) using the therapeutic and/or preventive agent.Type: ApplicationFiled: April 22, 2021Publication date: June 22, 2023Applicants: NEOPHARMA JAPAN CO., LTD., NAGASAKI UNIVERSITYInventors: Kiyoshi KITA, Kouichi MORITA, Jiro YASUDA, Yasuteru SAKURAI, Satofumi KAWATA, Tohru TANAKA, Motoyasu TOMIOKA, Kiyotaka FUJINE
-
Patent number: 11633505Abstract: [Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.Type: GrantFiled: December 9, 2013Date of Patent: April 25, 2023Assignees: National University Corporation Kumamoto University, University of Occupational and Enviromental Health, Japan, SBI Pharmaceuticals Co., Ltd.Inventors: Tetsuya Yoneda, Shigeru Nishizawa, Junkoh Yamamoto, Tohru Tanaka, Hidenori Itoh
-
Patent number: 11421204Abstract: A stem cell removing method that certainly-removes an undifferentiated stem cell is provided. For this object, a cell group including a stem cell and a somatic cell performed differentiation induction is cultivated in culture medium composition including photosensitizer. Light of a specific wavelength is irradiated with the cell group, and the stem cell is removed, selectively. The stem cell is a pluripotent stem cell or a somatic stem cell. The pluripotent stem cell includes either an ES cell (Embryonic Stem Cell) or an iPS cell (induced Pluripotent Stem Cell). Also, somatic stem cell includes any one of a germ stem cell, a productive cell, a pluripotent stem cell and a stem cell having unipotency.Type: GrantFiled: April 6, 2016Date of Patent: August 23, 2022Assignees: REPROCELL INCORPORATED, SBI PHARMACEUTICALS CO., LTD.Inventors: Shunsuke Yoshida, Mitsuru Inamura, Tohru Tanaka, Hiroyuki Ishikawa, Hidenori Ito
-
Publication number: 20220249417Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.Type: ApplicationFiled: February 28, 2022Publication date: August 11, 2022Inventors: Tohru Tanaka, Hidenori Ito, Ko Rii
-
Patent number: 11266619Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.Type: GrantFiled: November 28, 2018Date of Patent: March 8, 2022Assignees: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Tohru Tanaka, Hidenori Ito, Ko Rii
-
Patent number: 11123320Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.Type: GrantFiled: May 21, 2018Date of Patent: September 21, 2021Assignees: SBI PHARMACEUTICALS, CO., LTD., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITYInventors: Tohru Tanaka, Kiwamu Takahashi, Keiji Inoue, Motoaki Saito, Masayuki Tsuda, Hideo Fukuhara, Takahira Kuno, Shogo Shimizu
-
Publication number: 20200297674Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.Type: ApplicationFiled: November 28, 2018Publication date: September 24, 2020Inventors: Tohru Tanaka, Hidenori Ito, Ko Rii
-
Publication number: 20200163917Abstract: various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.Type: ApplicationFiled: May 21, 2018Publication date: May 28, 2020Inventors: Tohru TANAKA, Kiwamu TAKAHASHI, Keiji INOUE, Motoaki SAITO, Masayuki TSUDA, Hideo FUKUHARA, Takahira KUNO, Shogo SHIMIZU
-
Patent number: 10022345Abstract: The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs.Type: GrantFiled: November 30, 2015Date of Patent: July 17, 2018Assignee: SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata
-
Publication number: 20180127726Abstract: A stem cell removing method that certainly-removes an undifferentiated stem cell is provided. For this object, a cell group including a stem cell and a somatic cell performed differentiation induction is cultivated in culture medium composition including photosensitizer. Light of a specific wavelength is irradiated with the cell group, and the stem cell is removed, selectively. The stem cell is a pluripotent stem cell or a somatic stem cell. The pluripotent stem cell includes either an ES cell (Embryonic Stem Cell) or an iPS cell (induced Pluripotent Stem Cell). Also, somatic stem cell includes any one of a germ stem cell, a productive cell, a pluripotent stem cell and a stem cell having unipotency.Type: ApplicationFiled: April 6, 2016Publication date: May 10, 2018Applicants: REPROCELL INCORPORATED, SBI PHARMACEUTICALS CO., LTD.Inventors: Shunsuke YOSHIDA, Mitsuru INAMURA, Tohru TANAKA, Hiroyuki ISHIKAWA, Hidenori ITO
-
Publication number: 20180125805Abstract: The present invention addresses the problem of providing a prophylactic/therapeutic agent which is inexpensive, has little adverse side effects and is effective against persistent virus infections. A 5-aminolevulinic acid compound represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group) or a salt thereof can be used as a prophylactic and/or therapeutic agent for virus infections to prevent proliferation of viruses.Type: ApplicationFiled: March 18, 2016Publication date: May 10, 2018Applicant: SBI Pharmaceuticals Co., Ltd.Inventors: Tohru TANAKA, Motowo NAKAJIMA, Takeshi HARA
-
Patent number: 9962350Abstract: It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group) or salts thereof as an agent for improving a normal development rate of a fertilized egg.Type: GrantFiled: July 10, 2015Date of Patent: May 8, 2018Assignees: SBI Pharmaceuticals Co., Ltd., Yamagata UniversityInventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Osamu Nakajima
-
Patent number: 9937138Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: April 10, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9901558Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: February 27, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9895331Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).Type: GrantFiled: July 11, 2013Date of Patent: February 20, 2018Assignees: The University of Tokyo, SBI Pharmaceuticals Co., Ltd.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Hidenori Ito, Kiwamu Takahashi, Kouji Matsushima, Satoshi Ueha, Jun Abe
-
Patent number: 9772286Abstract: It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.Type: GrantFiled: June 20, 2011Date of Patent: September 26, 2017Assignees: SBI Pharmaceuticals Co., Ltd., National University Corporation Kochi UniversityInventors: Keiji Inoue, Taro Shuin, Mutsuo Furihata, Yoshihiko Hirao, Tohru Tanaka